ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Chemotherapy-Induced Hair Loss: Insights and Effective Strategies

Masonic Cancer Center, University of Minnesota

M. Hordinsky

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Pirtobrutinib in CLL: Current and Potential Utility in the Treatment…

Nicole Lamanna

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New…

2024 ESMO Annual Meeting Insights Hub

S. Banerjee

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta